Aldara™ Cream, 5% (Imiquimod)


Aldara Cream, 5% (Imiquimod)







  • Imiquimod is part of a new class of drugs called immune response modifiers.
  • It stimulates the innate immune response through interferon- a production, as well as acquired immunity by activating T-helper 1 cells.
  • The result of the release of cytokines, such as TNF-a and INF-a, is activation of both anti-viral and anti-tumor immunity that can be prolonged in the form of immune memory.
  • Toll-like receptor 7 on antigen presenting cells are key to their activation by imiquimod.

There are limitations for regulators, pharmaceutical companies and pharmaceutical sales representatives to present clinical evidence following development of product monograph and drug approval. The product monograph is the starting point for this A-Detail™. It also contains evidence-based decision making processes, current standards of practice and clinical experience to provide a practical approach to the treatment of this condition.

Disclaimer: This A-Detail™ is meant to be a practical guide and does not necessarily reflect all risks, side-effects or situations associated with this product.

Next:   Clinical Experience